SCHEMBL257228

SCHEMBL257228

O=C(O)c1ccc(Br)cc1C(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48
DGAT1 O75907 1/20 0.43
MYC P01106 1/20 0.41
NR4A1 P22736 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GPR35 Q9HC97 1/20 0.40
ACLY P53396 1/20 0.40
APEX1 P27695 1/20 0.39
KCNK2 O95069 1/20 0.38
KCNK10 P57789 1/20 0.38
CYP1A2 P05177 2/20 0.38
CES2 O00748 1/20 0.38
GALR3 O60755 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197100 0.83 DGAT1 (0.42) KDM4EGLADGAT1KMT2ACYP1A2
SCHEMBL11613901 0.82 KDM4E (0.50) KDM4EGLADGAT1MYCNR4A1
SCHEMBL3194641 0.81 KDM4E (0.48) KDM4EGLAMYCNR4A1MEN1
SCHEMBL29005696 0.79 KDM4E (0.47) KDM4EGLAMYCNR4A1MEN1
SCHEMBL19136407 0.79 NR4A2 (0.48) KDM4EGLADGAT1HPGDCASP1
SCHEMBL31335669 0.78 ALDH1A1 (0.55) KDM4EMYCMEN1KMT2ACYP1A2
SCHEMBL20605963 0.78 KEAP1 (0.50) KDM4EMEN1KMT2AAPEX1CYP1A2
SCHEMBL14122795 0.78 ACE2 (0.49) KDM4EMYCMEN1KMT2ACYP1A2
SCHEMBL8571636 0.77 SMN1; SMN2 (0.57) KDM4EMYCNR4A1MEN1KMT2A
SCHEMBL27822471 0.77 CSNK2A1 (0.50) MEN1KMT2AACLYCYP1A2SORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 KDM4E 2413/4885GLA 2833/4885DGAT1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.